Quantum Biopharma (QNTM) Cash & Equivalents (2018 - 2026)

Quantum Biopharma has reported Cash & Equivalents for 9 years, with the latest figure at $4.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 23.41% year-over-year to $4.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (up 23.41% YoY) and the FY2025 annual result came in at $1.9 million, down 68.22% from the prior year.
• Cash & Equivalents grew to $4.3 million in Q1 2026 per QNTM's latest filing, from $1.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $31.6 million in Q2 2022 and troughed at $445944.0 in Q3 2025.
• A 5-year average of $9.6 million and a median of $4.3 million in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 85.71% in 2025, then increased 23.41% in 2026.
• Over 5 years, Cash & Equivalents stood at $17.0 million in 2022, then sank by 78.6% to $3.6 million in 2023, then surged by 65.0% to $6.0 million in 2024, then slumped by 68.22% to $1.9 million in 2025, then surged by 127.88% to $4.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $4.3 million, $1.9 million, and $445944.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.